Kronbichler A, et al. - Via 197 patients enrolled in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial, the researchers determined the frequency of venous thromboembolic events (VTEs) observed in the RAVE trial and recognized novel potential risk factors. In univariate analyses, heart involvement, a positive test for proteinase 3 (PR3)-ANCA, pulmonary hemorrhage and the presence of red blood cell casts as associated with the onset of VTE were identified. however, the associations among heart involvement, positive PR3-ANCA, pulmonary hemorrhage, and urinary red blood cell casts remained significant in the multivariate models. Hence, positive PR3-ANCA, heart involvement, and the presence of red blood cell cast in patients with ANCA-associated vasculitis with pulmonary hemorrhage were at an increased risk of developing VTEs. To validate and extend these findings and to examine the mechanisms of hypercoagulability in these patients with the aim of informing potential targets for therapeutic intervention, further studies are suggestive.